Summary of Consort Medical plc (LON:CSRT) Ratings as of Apr 17, 2018

April 17, 2018 - By Mary Markley

Consort Medical plc (LON:CSRT) Corporate Logo

Consort Medical plc (LON:CSRT) Ratings Coverage

Total analysts of 4 have positions in Consort Medical PLC (LON:CSRT) as follows: 3 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 75%. Since November 9, 2017 according to StockzIntelligence Inc Consort Medical PLC has 5 analyst reports. On Thursday, November 9 the stock has “Buy” rating by Stifel Nicolaus. On Tuesday, December 5 the rating was maintained by Shore Capital with “Buy”. The stock rating was upgraded by Numis Securities to “Add” on Thursday, February 8. On Wednesday, December 6 the stock has “Hold” rating by Numis Securities. The company rating was downgraded by N+1 Singer on Tuesday, December 5. Listed here are Consort Medical plc (LON:CSRT) PTs and latest ratings.

08/02/2018 Broker: Numis Securities Rating: Add New Target: GBX 1333.00 Upgrade
06/12/2017 Broker: Numis Securities Rating: Hold Old Target: GBX 1084.00 New Target: GBX 1144.00 Maintain
05/12/2017 Broker: N+1 Singer Rating: Hold Downgrade
05/12/2017 Broker: Shore Capital Rating: Buy Maintain
09/11/2017 Broker: Stifel Nicolaus Rating: Buy Old Target: GBX 1250.00 New Target: GBX 1250.00 Maintain

CSRT reached GBX 1128.0001 on during the last trading session after GBX 0.0001 change.Consort Medical plc has volume of 349 shares. Since April 17, 2017 CSRT has 0.00% and is . CSRT underperformed by 11.55% the S&P 500.

Consort Medical plc operates as one-stop developer and maker of drugs and premium drug delivery devices.The company has 552.55 million GBP market cap. It operates through two divisions, Bespak and Aesica.28.27 is the P/E ratio. The firm provides innovative life improving treatments to patients across worldwide through the design, development, and manufacture of medical devices for inhaled, injectable, nasal, and ocular drug delivery, as well as point of care diagnostics products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: